CrossrefInfokarte
Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand
PharmacoEconomics - Open · 2025-01 · 9 (1) · 69-81
DOI: 10.1007/s41669-024-00526-2 ↗Abstract
Kein Abstract verfügbar.
EUVIMED